|Bid||0.00 x 1200|
|Ask||0.00 x 1400|
|Day's range||66.40 - 67.99|
|52-week range||52.65 - 71.70|
|Beta (5Y monthly)||0.17|
|PE ratio (TTM)||106.20|
|Forward dividend & yield||1.45 (2.19%)|
|Ex-dividend date||11 Aug 2022|
|1y target est||71.90|
Shares of Compugen (NASDAQ: CGEN), a clinical-stage biotech company that specializes in immunology therapies to treat cancer, saw its shares rise 16.5% on Wednesday. The stock closed on Tuesday at $1.03, then opened on Wednesday at $1.01, before jumping to $1.23 in the late afternoon and closing at $1.20. The stock has been volatile, with a 52-week low of $0.51 and a 52-week high of $4.88.
The acquisition of Neogene is set to give AstraZeneca (AZN) access to the latter's next-generation T-cell receptor therapies.
WILMINGTON, Del., November 30, 2022--AstraZeneca will present 47 abstracts showcasing new data from across its hematology portfolio and clinical pipeline, demonstrating its commitment to redefining care for hard-to-treat blood diseases at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, December 10 to 13, 2022.